Evidence map›Paper›PMID 33148458›Full record

ArticleGene2021

Functional characterization of Polr3a hypomyelinating leukodystrophy mutations in the S. cerevisiae homolog, RPC160.

Robyn D Moir, Christian Lavados, JaeHoon Lee, Ian M Willis

Open access · greenAbstract read
In one paragraph

Article in Gene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Defective myelination in an RNA polymerase III mutant leukodystrophic mouse.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  6. RNA Polymerase III Subunit Mutations in Genetic Diseases.Frontiers in molecular biosciences · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Robyn D MoirDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: robyn.moir@einsteinmed.org.
Christian LavadosGraduate Program in Biomedical Science, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
JaeHoon LeeDepartment of Medicine (Cardiology), Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Ian M WillisDepartments of Biochemistry and Systems and Computational Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Albert Einstein College of Medicine · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2M
MAF1 Function and Metabolic InefficiencyR01GM120358 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI WILLIS, IAN M · 2016 to 2019
$2.2M
Studies on Pol III-Associated LeukodystrophyR21HD097557 · NICHD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI MOIR, ROBYN, WILLIS, IAN M · 2019 to 2020
$459k
NCI NIH HHS P30 CA013330NICHD NIH HHS R21 HD097557NIGMS NIH HHS R01 GM120358
6 · The paper itself

Abstract

Mutations in RNA polymerase III (Pol III) cause hypomeylinating leukodystrophy (HLD) and neurodegeneration in humans. POLR3A and POLR3B, the two largest Pol III subunits, together form the catalytic center and carry the majority of disease alleles. Disease-causing mutations include invariant and highly conserved residues that are predicted to negatively affect Pol III activity and decrease transcriptional output. A subset of HLD missense mutations in POLR3A cluster in the pore region that provides nucleotide access to the Pol III active site. These mutations were engineered at the corresponding positions in the Saccharomyces cerevisiae homolog, Rpc160, to evaluate their functional deficits. None of the mutations caused a growth or transcription phenotype in yeast. Each mutation was combined with a frequently occurring pore mutation, POLR3A G672E, which was also wild-type for growth and transcription. The double mutants showed a spectrum of phenotypes from wild-type to lethal, with only the least fit combinations showing an effect on Pol III transcription. In one slow-growing temperature-sensitive mutant the steady-state level of tRNAs was unaffected, however global tRNA synthesis was compromised, as was the synthesis of RPR1 and SNR52 RNAs. Affinity-purified mutant Pol III was broadly defective in both factor-independent and factor-dependent transcription in vitro across genes that represent the yeast Pol III transcriptome. Thus, the robustness of yeast Rpc160 to single Pol III leukodystrophy mutations in the pore domain can be overcome by a second mutation in the domain.

Indexed as

DNA-Binding ProteinsDNA-Directed RNA PolymerasesHumansPelizaeus-Merzbacher DiseaseRNA Polymerase IIIRNA, TransferSaccharomyces cerevisiaeTranscription, GeneticDNA-Binding ProteinsDNA-Directed RNA PolymerasesPOLR3A protein, humanRNA Polymerase IIIRNA, TransferPOLR3A hypomyelinating leukodystrophyRNA polymerase IIIRPC160RPR1SNR52Transcription

Identifiers

PMID33148458
PMCPMC8423089
OpenAlexW3093625022

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.